Effect of short-term interferon-beta treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23

Kurtuncu M., Tuzun E., TURKOGLU R., PETEK-BALCI B., Icoz S., Pehlivan M., ...Daha Fazla

CYTOKINE, cilt.59, sa.2, ss.400-402, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/j.cyto.2012.05.004
  • Dergi Adı: CYTOKINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.400-402
  • Anahtar Kelimeler: Multiple sclerosis, Cytokine, Interleukins, Th17, Th1, AUTOIMMUNE ENCEPHALOMYELITIS, MS PATIENTS, THERAPY, CELLS, INTERLEUKIN-12, RESPONDERS, DISEASE, GAMMA
  • İstanbul Üniversitesi Adresli: Evet

Özet

Therapeutic effect of interferon-beta (IFN-beta) treatment has been associated with modulation of the balance between Th1, Th17, Th2 and regulatory T (Treg) cells, whereas the impact of disease modifying drugs on Th9-immunity in multiple sclerosis (MS) has not been studied. To investigate the short-term effects of IFN-beta treatment on cytokines in MS, we determined serum levels of IL-17, IL-23, IL-10, IL-4, IFN-gamma, IL-9 and TGF-beta in relapsing remitting MS patients before and 2 months after IFN-beta treatment by ELISA. MS patients showed increased IL-17, IL-23 and IL-4 levels and decreased IL-9 levels as compared to healthy controls. IFN-beta treatment only reduced IL-17 and IL-23 levels, whereas the levels of other cytokines remained unchanged. IFN-beta treatment appears to exert its earliest therapeutic effect on Th17-immunity. The influence of IL-9 on MS pathogenesis needs to be further studied. (C) 2012 Elsevier Ltd. All rights reserved.